Misplaced Pages

Adegramotide

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Experimental cancer drug
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article needs to be updated. Please help update this article to reflect recent events or newly available information. (August 2021)
The topic of this article may not meet Misplaced Pages's general notability guideline. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.
Find sources: "Adegramotide" – news · newspapers · books · scholar · JSTOR (August 2017) (Learn how and when to remove this message)
(Learn how and when to remove this message)
Pharmaceutical compound
Adegramotide
Legal status
Legal status
  • experimental
Identifiers
IUPAC name
  • L-tryptophyl-L-alanyl-L-prolyl-L-valyl-L-leucyl-L-alpha-aspartyl-L-phenylalanyl-L-alanyl-L-prolyl-L-prolyl-glycyl-L-alanyl-L-seryl-L-alanyl-L-tyrosyl-glycyl-L-seryl-L-leucine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC87H123N19O24
Molar mass1819.050 g·mol
3D model (JSmol)
SMILES
  • C(C(=O)N(CO)C(=O)N(C)C(=O)N(CC1=CC=C(C=C1)O)C(=O)NCC(=O)N(CO)C(=O)N(CC(C)C)C(=O)O)NC(=O)CNC(=O)2CCCN2C(=O)3CCCN3C(=O)(C)NC(=O)(CC4=CC=CC=C4)NC(=O)(CC(=O)O)NC(=O)(CC(C)C)NC(=O)(C(C)C)NC(=O)5CCCN5C(=O)(C)NC(=O)(CC6=CNC7=CC=CC=C76)N
InChI
  • InChI=InChI=1S/C87H123N19O24/c1-44(2)33-58(100-83(125)71(46(5)6)103-82(124)66-24-17-30-104(66)84(126)49(9)94-74(116)56(88)37-53-39-89-57-22-15-14-21-55(53)57)77(119)99-61(38-70(112)113)78(120)98-60(35-51-19-12-11-13-20-51)76(118)95-50(10)85(127)106-32-18-25-67(106)86(128)105-31-16-23-65(105)81(123)91-40-68(110)92-47(7)72(114)102-64(43-108)79(121)93-48(8)73(115)97-59(36-52-26-28-54(109)29-27-52)75(117)90-41-69(111)96-63(42-107)80(122)101-62(87(129)130)34-45(3)4/h11-15,19-22,26-29,39,44-50,56,58-67,71,89,107-109H,16-18,23-25,30-38,40-43,88H2,1-10H3,(H,90,117)(H,91,123)(H,92,110)(H,93,121)(H,94,116)(H,95,118)(H,96,111)(H,97,115)(H,98,120)(H,99,119)(H,100,125)(H,101,122)(H,102,114)(H,103,124)(H,112,113)(H,129,130)/t47-,48-,49-,50-,56-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,71-/m0/s1
  • Key:QMUKFZMAYHSADK-MZDDNWLQSA-N

Adegramotide (DSP-7888) is an experimental drug intended for treatment of various hematologic malignancies and solid tumors, including glioblastoma multiforme. It is a peptide vaccine and has finished phase I clinical trials and phase II clinical trials.

As of 14 December 2021, phase III clinical research has been cancelled due to low efficacy markers during interim review of study data for Ombipepimut-S Emulsion (DSP-7888) in combination with Bevacizumab.

The phase III trials for DSP-7888 with checkpoint inhibitors for platinum-resistant ovarian cancer, as of 13 August 2024, is still continuing as planned.

References

  1. Spira A, Hansen AR, Harb WA, Curtis KK, Koga-Yamakawa E, Origuchi M, Li Z, Ertik B, Shaib WL (July 2021). "Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies". Targeted Oncology. 16 (4): 461–469. doi:10.1007/s11523-021-00813-6. PMC 8266707. PMID 33939067.
  2. Boston Biomedical (11 May 2017). "A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy". ClinicalTrials.gov. U.S. National Library of Medicine.
  3. Suginobe; et al. "Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors". pubchem.ncbi.nlm.nih.gov.
  4. ^ Sumitomo Dainippon Pharma Oncology Inc. "Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma". www.prnewswire.com. Archived from the original on 2024-08-13. Retrieved 2024-08-13.
  5. "Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888 in Patients with Glioblastoma Terminates | Sumitomo Pharma". www.sumitomo-pharma.com. Archived from the original on 2024-08-13. Retrieved 2024-08-13.
  6. "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors". clinicaltrials.gov. Archived from the original on 2024-08-13. Retrieved 2024-08-13.


Stub icon

This article about vaccines or vaccination is a stub. You can help Misplaced Pages by expanding it.

Categories: